J&J Medical Connect
icotrokinra
+ Save link
J&J Medical Connect

Connect with us

Connect with us

This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

icotrokinra

Medical Information

Icotrokinra - Treatment of Psoriatic Arthritis - ICONIC-PsA Program

Last Updated: 09/15/2025

SUMMARY  

  • Icotrokinra (JNJ-77242113) is a targeted oral peptide that selectively binds the interleukin-23 (IL-23) receptor and inhibits IL-23 pathway signaling.1
  • Icotrokinra is being studied in 2 psoriatic arthritis (PsA) phase 3 clinical trials: ICONIC-PsA 1 and ICONIC-PsA 2. Results are not currently available.2-4
  • ICONIC-PsA 1 and ICONIC-PsA 2 are ongoing, phase 3, multicenter, randomized, double-blind, placebo-controlled studies evaluating the safety and efficacy of icotrokinra in biologic-naïve and biologic-experienced adult patients with active PsA, respectively.2-4
  • The design of the ICONIC-PsA phase 3 clinical trial program was informed and supported by exploratory assessments from FRONTIER-1 study.2
    • FRONTIER-1 is a completed phase 2b multicenter, randomized, placebo-controlled study assessing the safety and efficacy of icotrokinra in adult patients with moderate to severe plaque psoriasis (PsO).5

CLINICAL STUDIES

Phase 3 Studies – ICONIC-PsA 1 and ICONIC-PsA 2

Merola et al (2025)2 designed two phase 3, multicenter, randomized, double-blind, placebo-controlled studies to evaluate the safety and efficacy of icotrokinra in adult patients with active PsA (ICONIC-PsA 1, N=540; ICONIC-PsA 2, N=750), respectively. Results are not currently available.

Study Design/Methods


Select Inclusion/Exclusion Criteria for ICONIC-PsA 12,3
Inclusion Criteria
Exclusion Criteria
  • Active PsA ≥3 months
  • Met CASPAR at screening
  • ≥3 TJC and SJC
  • CRP ≥0.1 mg/dL
  • ≥1 PsA subtype: distal interphalangeal joint involvement, polyarticular arthritis (without rheumatoid nodules), arthritis mutilans, asymmetric peripheral arthritis, or spondylitis with peripheral arthritis
  • Active plaque PsO with ≥1 psoriatic plaque
    ≥2 cm in diameter or psoriatic nail changes
  • Previous treatment with biologic DMARDs for PsA or PsO
  • Diagnosis of other inflammatory diseases (eg, RA, SLE, or Lyme disease)
Abbreviations: CASPAR, ClASsification criteria for Psoriatic ARthritis; CRP, C-reactive protein; DMARD, disease-modifying antirheumatic drug; PsA, psoriatic arthritis; PsO, psoriasis; RA, rheumatoid arthritis; SJC, swollen joint count; SLE, systemic lupus erythematosus; TJC, tender joint count



Select Inclusion/Exclusion Criteria for ICONIC-PsA 22,4
Inclusion Criteria
Exclusion Criteria
  • Patient must have previously received treatment with 1 biologic agent for PsA or PsO, with the reason for discontinuation documented  
  • Active PsA ≥3 months
  • Met CASPAR at screening
  • ≥3 TJC and SJC
  • CRP ≥0.1 mg/dL
  • ≥1 PsA subtype: distal interphalangeal joint involvement, polyarticular arthritis (without rheumatoid nodules), arthritis mutilans, asymmetric peripheral arthritis, or spondylitis with peripheral arthritis
  • Active plaque PsO with ≥1 psoriatic plaque
    ≥2 cm in diameter or psoriatic nail changes
  • Diagnosis of other inflammatory diseases (eg, RA, SLE, or Lyme disease)
Abbreviations: CASPAR, ClASsification criteria for Psoriatic ARthritis; CRP, C-reactive protein; DMARD, disease-modifying antirheumatic drug; PsA, psoriatic arthritis; PsO, psoriasis; RA, rheumatoid arthritis; SJC, swollen joint count; SLE, systemic lupus erythematosus; TJC, tender joint count

Primary, Secondary, and Safety Endpoints for ICONIC-PsA 1 and ICONIC-PsA 22-4 
Primary Endpoint  
  • Proportion of patients who achieve an ACR 20 response at week 16
Secondary Endpoints
  • At week 16, proportion of patients achieving:
    • ACR 50/70 responses
    • PASI 75/90/100 responses (with baseline BSA ≥3% and IGA score of ≥2 at baseline)
    • IGA 0/1 response (with ≥2 grade improvement from baseline)
    • Resolution of enthesitis
    • Resolution of dactylitis
    • MDA
  • At week 16, change from baseline in:
    • HAQ-DI score
    • SF-36 PCS score
    • Enthesitis score (LEI)
    • Dactylitis score (DSS)
    • FACIT-Fatigue score
Safety
  • AEs
  • Clinical laboratory tests
  • Vital signs
Abbreviations: ACR 20/50/70, ≥20%/50%/70% improvement in American College of Rheumatology response criteria; AE, adverse events; BSA, body surface area; DSS, Dactylitis Severity Score; FACIT-Fatigue, Functional Assessment of Chronic Illness Therapy-Fatigue; HAQ-DI, Health Assessment Questionnaire-Disability Index; IGA, Investigator’s Global Assessment; LEI, Leeds Enthesitis Index; MDA, minimal disease activity; PASI 75/90/100, ≥75%/90%/100% improvement in Psoriasis Area and Severity Index; SF-36 PCS, 36-Item Short Form Survey physical component summary

A screenshot of a graph AI-generated content may be incorrect.ICONIC-PsA Program Study Designs2 

Abbreviations: ACR20, ≥20% improvement in American College of Rheumatology response criteria; CASPAR, ClASsification criteria for Psoriatic ARthritis; CRP, C-reactive protein; DMARD, disease-modifying antirheumatic drugs; ICO, icotrokinra; PBO, placebo; PE, primary endpoint; PO, oral; PsA, psoriatic arthritis; QD, once daily; R, randomization; SJC, swollen joint count; TJC, tender joint count
aN=540 was estimated to have ≥90% power to detect a significant statistical difference between ICO and PBO.                                          

A chart with text and numbers AI-generated content may be incorrect.

Abbreviations: ACR20, ≥20% improvement in American College of Rheumatology response criteria; CASPAR, ClASsification criteria for Psoriatic ARthritis; CRP, C-reactive protein; DMARD, disease-modifying antirheumatic drugs; ICO, icotrokinra; PBO, placebo; PE, primary endpoint; PO, oral; PsA, psoriatic arthritis; QD, once daily; R, randomization; SJC, swollen joint count; TJC, tender joint count
aN=750 was estimated to have ≥90% power to detect a significant statistical difference between ICO and PBO.
bPatients must have been previously treated with 1 biologic for PsA or PsO and the reason for discontinuation must be documented.

LITERATURE SEARCH

A literature search of MEDLINE®, EMBASE®, BIOSIS Previews®, and DERWENT® (and/or other resources, including internal/external databases) was conducted on 24 July 2025.

 

References

Show
1 Gooderham M, Lain E, Bissonnette R, et al. Phase 3 results from an innovative trial design of treating plaque psoriasis involving difficult-to-treat, high-impact sites with icotrokinra, a targeted oral peptide that selectively inhibits the IL-23-receptor. Poster presented at: SID Annual Meeting; May 7-10, 2025; San Diego, CA.  
2 Merola JF, Mease PJ, Coates LC, et al. Icotrokinra, a first-in-class, targeted oral peptide, in participants with psoriatic disease: exploratory assessments from a phase 2 psoriasis study informing a phase 3 clinical program in psoriatic arthritis. Poster presented at: European Alliance of Associations for Rheumatology (EULAR); June 11-14, 2025; Barcelona, Spain.  
3 Janssen Research & Development, LLC. A study to evaluate the efficacy and safety of JNJ-77242113 (Icotrokinra) in biologic-naïve participants with active psoriatic arthritis (ICONIC-PsA 1). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2025 July 22]. Available from: https://clinicaltrials.gov/study/NCT06878404 NLM Identifier: NCT06878404.  
4 Janssen Research & Development, LLC. A study to evaluate the efficacy and safety of icotrokinra (JNJ-77242113) in biologic-experienced participants with active psoriatic arthritis (ICONIC-PsA 2). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2025 July 20]. Available from: https://clinicaltrials.gov/study/NCT06807424 NLM Identifier: NCT06807424.  
5 Janssen Research & Development, LLC. A study of JNJ-77242113 in participants with moderate-to-severe plaque psoriasis (FRONTIER 1). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2025 May 25]. Available from: https://www.clinicaltrials.gov/study/NCT05223868 NLM Identifier: NCT05223868.